Antigens such as the N protein, E protein and S protein of the new coronavirus can be used as immunogens to stimulate plasma cells to produce specifific antibodies after the virus infects the human body. The COVID19 antigen test can directly detect whether the human sample contains the COVID19. The diagnosis is fast, accurate, and requires low equipment and personnel.
![COVID19](https://ecdn6.globalso.com/upload/p/1293/source/2024-03/65ebd08d64f5b10166.jpg)
![COVID19](https://ecdn6.globalso.com/upload/p/1293/source/2024-03/65ebd08eac0ff31947.jpg)
The Rapid COVID-19 Antigen Test is a colloidal gold immunochromatography intended for the qualitative detection of nucleocapsid antigens from COVID-19 in human nasal swabs ,throat swabs or saliva from individuals who are suspected of COVID-19 by their healthcare provider. The novel coronaviruses belong to the β genus. COVID-19 is an acute respiratory infectious disease. People are generally susceptible. Currently, the patients infected by the novel coronavirus are the main source of infection; asymptomatic infected people can also be an infectious source. Based on the current epidemiological investigation, the incubation period is 1 to 14 days, mostly 3 to 7 days. The main manifestations include fever, fatigue and dry cough. Nasal congestion, runny nose, sore throat, myalgia and diarrhea are found in a few cases. Results are for the identification of COVID-19 nucleocapsid antigen. The antigen is generally detectable in upper respiratory samples or lower respiratory samples during the acute phase of infection. The positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. The positive results do not rule out bacterial infection or co-infection with other viruses. The antigen detected may not be the definite cause of disease. The negative results do not rule out COVID-19 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. The negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19 and confirmed with a moecular assay, if necessary for patient management.
![e2c6b668df46a4fe9e48790e48c70a4](https://ecdn6.globalso.com/upload/p/1293/source/2024-03/65ebd08fe33dd20525.jpg)
Negative
![b547f4386c1032b00b80c5de261e265](https://ecdn6.globalso.com/upload/p/1293/source/2024-03/65ebd090d76d172797.jpg)
Positive
![cb6993dcb6511c78808890fec684c9b](https://ecdn6.globalso.com/upload/p/1293/source/2024-03/65ebd091c72e540216.jpg)